28th Feb 2007 16:33
28 February 2007
Shire plc (the "Company")
The Company announces that on 27 February 2007 the following Persons Discharging Managerial Responsibility ("PDMRs") were granted awards under the Shire plc Portfolio Share Plan (the "Plan").
Awards of Stock Settled Appreciation Rights ("SARs") under Part A of the Plan
Name of PDMR Type of Security No of Ordinary Exercise Shares or ADRs price Matthew Emmens (Executive American Depositary 93,840 $64.10 Director)* Receipt ("ADR") Angus Russell (Executive Ordinary Share 117,495 ‚£10.99 Director)* Michael Cola ADR 19,334 $64.10 David Pendergast ADR 17,667 $64.10 Tatjana May Ordinary Share 40,000 ‚£10.99 Barbara Deptula ADR 11,667 $64.10 Eliseo Salinas ADR 10,667 $64.10 Joseph Rus ADR 11,334 $64.10 Anita Graham ADR 10,000 $64.10 Caroline West ADR 15,000 $64.10
*Awards to Executive Directors are subject to performance targets
SARs will normally vest after three years, subject to any performance targets. Once vested, SARs will be capable of exercise for a period of two years. No consideration was paid for the grant of the SARs.
Performance Share Awards ("PSP Awards") under Part B of the Plan
Name of PDMR Type of Security No of Ordinary Market Shares or ADRs value Matthew Emmens (Executive American Depositary 70,380 $64.10 Director)* Receipt ("ADR") Angus Russell (Executive Ordinary Share 80,000 ‚£10.99 Director)* Michael Cola ADR 14,000 $64.10 David Pendergast ADR 13,000 $64.10 Tatjana May Ordinary Share 30,000 ‚£10.99 Barbara Deptula ADR 10,000 $64.10 Eliseo Salinas ADR 8,334 $64.10 Joseph Rus ADR 8,334 $64.10 Anita Graham ADR 8,334 $64.10
*Awards to Executive Directors are subject to performance targets
The PSP awards will normally vest after three years, subject to any performance targets. Once vested, sufficient ordinary shares or ADRs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of PSP awards.
T MayCompany Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company's website: www.shire.com.
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592Registered Office as above
SHIRE PLCRelated Shares:
Shire